144 related articles for article (PubMed ID: 10191675)
1. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
Dangas G; Fuster V
Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
Dangas G; Colombo A
Am Heart J; 1999 Jul; 138(1 Pt 2):S16-23. PubMed ID: 10385787
[TBL] [Abstract][Full Text] [Related]
3. Drugs for percutaneous coronary interventions.
Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):100-2. PubMed ID: 15583527
[TBL] [Abstract][Full Text] [Related]
4. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
5. GP IIb/IIIa blockade during peripheral artery interventions.
Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
7. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
8. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.
Tcheng JE
J Interv Cardiol; 2006 Oct; 19(5):456-63. PubMed ID: 17020571
[TBL] [Abstract][Full Text] [Related]
9. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
10. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
Kandzari DE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
[TBL] [Abstract][Full Text] [Related]
11. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
12. IIb/IIIa inhibitors in acute myocardial infarction.
Montalescot G
Blood Coagul Fibrinolysis; 1999 Feb; 10 Suppl 1():S71-5. PubMed ID: 10070824
[TBL] [Abstract][Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions.
Pitts WR; Lange RA
Thromb Haemost; 1999 Sep; 82 Suppl 1():136-8. PubMed ID: 10695505
[TBL] [Abstract][Full Text] [Related]
14. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
[No Abstract] [Full Text] [Related]
15. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Van de Werf F
Thromb Haemost; 1997 Jul; 78(1):210-3. PubMed ID: 9198155
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
17. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
Meyer BJ
Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
[TBL] [Abstract][Full Text] [Related]
18. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
Ferguson JJ; Waly HM; Wilson JM
Eur Heart J; 1998 Apr; 19 Suppl D():D3-9. PubMed ID: 9597517
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet therapy in acute coronary syndromes.
Aragam KG; Bhatt DL
J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
[TBL] [Abstract][Full Text] [Related]
20. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
Muñiz-Lozano A; Rollini F; Franchi F; Angiolillo DJ
Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):197-213. PubMed ID: 23818658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]